Market Overview

Recap: Inovio Pharmaceuticals Q3 Earnings


Shares of Inovio Pharmaceuticals (NASDAQ:INO) increased 2.94% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 4.00% year over year to ($0.26), which missed the estimate of ($0.19).

Revenue of $236,178,000 up by 27145.14% year over year, which beat the estimate of $3,050,000.


Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.

Inovio Pharmaceuticals hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Nov 09, 2020

Time: 04:30 PM

ET Webcast URL:

Price Action

52-week high: $33.79

Company's 52-week low was at $2.19

Price action over last quarter: down 40.29%

Company Overview

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.


Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Earnings